Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis.

摘要

INTRODUCTION: This sub-analysis evaluated clinical safety and effectiveness ofbolus insulin aspart [with/without oral glucose-lowering drugs (OGLDs)] as theonly insulin therapy.METHODS: A1chieve was an international, multicenter, prospective, open-label,non-interventional, observational, 24-week study in people with type 2 diabetesmellitus starting/switching to biphasic insulin aspart 30, insulin detemir orinsulin aspart treatment (alone/in combination) in routine clinical practice.This sub-analysis evaluated clinical safety and effectiveness of bolus insulinaspart (+-OGLDs) as the only insulin therapy. Data were analyzed for all patients,insulin-experienced and insulin-naive sub-groups, and sub-groups defined by thenumber of OGLDs prescribed at baseline (no OGLDs, one OGLD or >=two OGLDs). Safetyand effectiveness endpoints were assessed at baseline and following 24?weeks'therapy.RESULTS: In total, 2,026 patients were included (insulin-experienced, n?=?561;insulin-naive, n?=?1,465) in this sub-analysis. Significant improvements frombaseline after 24?weeks' treatment with insulin aspart?+-?OGLDs were observedacross all sub-groups for: glycated hemoglobin (range of means across sub-groups -1.6 to -2.4%; p?